Ennis William J, Sui Audrey, Bartholomew Amelia
Department of Vascular Surgery, University of Illiniois Hospital and Health Sciences System , Chicago, Illinois. ; Department of Wound Healing and Tissue Repair, University of Illiniois Hospital and Health Sciences System , Chicago, Illinois. ; Department of Surgery, University of Illiniois Hospital and Health Sciences System , Chicago, Illinois.
Department of Vascular Surgery, University of Illiniois Hospital and Health Sciences System , Chicago, Illinois. ; Department of Wound Healing and Tissue Repair, University of Illiniois Hospital and Health Sciences System , Chicago, Illinois.
Adv Wound Care (New Rochelle). 2013 Sep;2(7):369-378. doi: 10.1089/wound.2013.0449.
The number of patients with nonhealing wounds has rapidly accelerated over the past 10 years in both the United States and worldwide. Some causative factors at the macro level include an aging population, epidemic numbers of obese and diabetic patients, and an increasing number of surgical procedures. At the micro level, chronic inflammation is a consistent finding.
A number of treatment modalities are currently used to accelerate wound healing, including energy-based modalities, scaffoldings, the use of mechano-transduction, cytokines/growth factors, and cell-based therapies. The use of stem cell therapy has been hypothesized as a potentially useful adjunct for nonhealing wounds. Specifically, mesenchymal stem cells (MSCs) have been shown to improve wound healing in several studies. Immune modulating properties of MSCs have made them attractive treatment options.
Current limitations of stem cell therapy include the potentially large number of cells required for an effect, complex preparation and delivery methods, and poor cell retention in targeted tissues. Comparisons of published and clinical trials are difficult due to cell preparation techniques, passage number, and the impact of the micro-environment on cell behavior.
MSCs may be more useful if they are preactivated with inflammatory cytokines such as tumor necrosis factor alpha or interferon gamma. This article will review the current literature with regard to the use of stem cells for wound healing. In addition the anti-inflammatory effects of MSCs will be discussed along with the potential benefits of stem cell preactivation.
在过去10年里,美国和全球范围内不愈合伤口患者的数量迅速增加。宏观层面的一些致病因素包括人口老龄化、肥胖和糖尿病患者数量众多以及外科手术数量不断增加。微观层面上,慢性炎症是一个常见的发现。
目前有多种治疗方式用于加速伤口愈合,包括基于能量的方式、支架、机械转导的应用、细胞因子/生长因子以及基于细胞的疗法。干细胞疗法已被认为是治疗不愈合伤口的一种潜在有用的辅助方法。具体而言,多项研究表明间充质干细胞(MSCs)可促进伤口愈合。MSCs的免疫调节特性使其成为有吸引力的治疗选择。
干细胞疗法目前的局限性包括产生效果可能需要大量细胞、制备和递送方法复杂以及在靶组织中的细胞留存率低。由于细胞制备技术、传代次数以及微环境对细胞行为的影响,已发表的研究和临床试验之间难以进行比较。
如果用炎性细胞因子如肿瘤坏死因子α或干扰素γ对MSCs进行预激活,它们可能会更有用。本文将综述目前关于干细胞用于伤口愈合的文献。此外,还将讨论MSCs的抗炎作用以及干细胞预激活的潜在益处。